000303025 001__ 303025
000303025 005__ 20250727021634.0
000303025 0247_ $$2doi$$a10.1016/j.ymthe.2025.07.014
000303025 0247_ $$2pmid$$apmid:40671675
000303025 0247_ $$2ISSN$$a1525-0016
000303025 0247_ $$2ISSN$$a1525-0024
000303025 0247_ $$2altmetric$$aaltmetric:179392190
000303025 037__ $$aDKFZ-2025-01472
000303025 041__ $$aEnglish
000303025 082__ $$a610
000303025 1001_ $$0P:(DE-He78)baf300324dc6b20752a9a684a2841381$$aNeukirch, Lasse$$b0$$eFirst author
000303025 245__ $$aNeo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles.
000303025 260__ $$aAmsterdam$$bElsevier$$c2025
000303025 3367_ $$2DRIVER$$aarticle
000303025 3367_ $$2DataCite$$aOutput Types/Journal article
000303025 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1753097944_5171
000303025 3367_ $$2BibTeX$$aARTICLE
000303025 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303025 3367_ $$00$$2EndNote$$aJournal Article
000303025 500__ $$a#EA:D120#LA:D210# / epub
000303025 520__ $$aPersonalized treatment has become a realistic option for tumor patients, accelerated by significantly reduced sequencing costs of tumor genomes and advances in vaccine formulations. The druggability of cancer neo-antigens caused by individual mutations is centered in this effort. We here use an AAV-based VLP platform to compose a neo-antigen specific protein vaccine that is effective in a murine prevention and treatment setting. Furthermore, we show that CD4+ T cell responses that are provided by the AAV capsid are crucial for an effective murine melanoma treatment. To uncover the optimal composition of a peptide vaccine we de-linked MHC-II helper peptides from the capsid and formulated an efficient neo-antigen specific vaccine, which showed the independence of CD4+ T cell response from tumor sequences. The findings are supported by clinical data of neo-antigen vaccinated tumor patients. Our results punctuate on the significance of MHC-II epitopes for CD8+ T cell responses and suggest a future use of AAVLPs as neo-epitope vaccines in personalized cancer treatments.
000303025 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000303025 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303025 7001_ $$0P:(DE-He78)c582340f180b3ff6ea9f732f17047d3e$$aUhrig-Schmidt, Silke$$b1$$eFirst author$$udkfz
000303025 7001_ $$0P:(DE-He78)340faceb181495b537c5b0031a305167$$avon Werthern, Katharina$$b2$$udkfz
000303025 7001_ $$0P:(DE-He78)5ab3e75a5a7c0a8d804f9833a1152067$$aTuch, Alexandra$$b3$$udkfz
000303025 7001_ $$aKraske, Joscha A$$b4
000303025 7001_ $$0P:(DE-He78)558f7ddc9b9893d0f57eb74e243cc4fd$$aLyu, Yanhong$$b5$$udkfz
000303025 7001_ $$0P:(DE-He78)4671d97058e8d2ddb314e6be4de0c403$$aLenoir, Bénédicte$$b6$$udkfz
000303025 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b7$$udkfz
000303025 7001_ $$0P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a$$aMeyer, Marten$$b8$$udkfz
000303025 7001_ $$aZörnig, Inka$$b9
000303025 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b10$$udkfz
000303025 7001_ $$0P:(DE-He78)0a9ff2c74a3fef06f552be5bb95bfd2d$$aSchmidt, Patrick$$b11$$eLast author$$udkfz
000303025 773__ $$0PERI:(DE-600)2001818-6$$a10.1016/j.ymthe.2025.07.014$$gp. S1525001625005490$$pnn$$tMolecular therapy$$vnn$$x1525-0016$$y2025
000303025 909CO $$ooai:inrepo02.dkfz.de:303025$$pVDB
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)baf300324dc6b20752a9a684a2841381$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c582340f180b3ff6ea9f732f17047d3e$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)340faceb181495b537c5b0031a305167$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ab3e75a5a7c0a8d804f9833a1152067$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)558f7ddc9b9893d0f57eb74e243cc4fd$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4671d97058e8d2ddb314e6be4de0c403$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000303025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a9ff2c74a3fef06f552be5bb95bfd2d$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000303025 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000303025 9141_ $$y2025
000303025 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL THER : 2022$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000303025 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bMOL THER : 2022$$d2025-01-06
000303025 9202_ $$0I:(DE-He78)D210-20160331$$kD210$$lGMP-Einheit Zelluläre Therapie$$x0
000303025 9200_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x0
000303025 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x0
000303025 9201_ $$0I:(DE-He78)D210-20160331$$kD210$$lGMP-Einheit Zelluläre Therapie$$x1
000303025 980__ $$ajournal
000303025 980__ $$aVDB
000303025 980__ $$aI:(DE-He78)D120-20160331
000303025 980__ $$aI:(DE-He78)D210-20160331
000303025 980__ $$aUNRESTRICTED